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OBJECTIVE—Cannabinoid receptor 1 (CB1) is localized in the
central nervous system and in peripheral tissues involved in
energy metabolism control. However, CB1 receptors are also
expressed at low level within the glomeruli, and the aim of this
study was to investigate their potential relevance in the patho-
genesis of proteinuria in experimental type 1 diabetes.
RESEARCH DESIGN AND METHODS—Streptozotocin-
induced diabetic mice were treated with N-(piperidin-1-yl)-
5-(4-iodophenyl)-1-(2,3-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide (AM251), a selective CB1-receptor antagonist, at
the dosage of 1 mg  kg
1  day
1 via intraperitoneal injection for
14 weeks. Urinary albumin excretion was measured by enzyme-
linked immunosorbent assay. CB1 receptor expression was stud-
ied by immunohistochemistry, immunoblotting, and real-time
PCR. Expression of nephrin, podocin, synaptopodin, and zonula
occludens-1 (ZO-1) was assessed by immunoﬂuorescence and
real-time PCR. Fibronectin, transforming growth factor-1 (TGF-
1), and connective tissue growth factor (CTGF) mRNA levels
were quantitated by real-time PCR.
RESULTS—In diabetic mice, the CB1 receptor was overex-
pressed within the glomeruli, predominantly by glomerular podo-
cytes. Blockade of the CB1 receptor did not affect body weight,
blood glucose, and blood pressure levels in either diabetic or
control mice. Albuminuria was increased in diabetic mice com-
pared with control animals and was signiﬁcantly ameliorated by
treatment with AM251. Furthermore, CB1 blockade completely
prevented diabetes-induced downregulation of nephrin, podocin,
and ZO-1. By contrast overexpression of ﬁbronectin, TGF-1,
and CTGF in renal cortex of diabetic mice was unaltered by
AM251 administration.
CONCLUSIONS—In experimental type 1 diabetes, the CB1
receptor is overexpressed by glomerular podocytes, and block-
ade of the CB1 receptor ameliorates albuminuria possibly via
prevention of nephrin, podocin, and ZO-1 loss. Diabetes 59:
1046–1054, 2010
D
iabetic nephropathy is characterized by in-
creased glomerular permeability to proteins
and excessive extracellular matrix accumula-
tion in the mesangium, eventually resulting in
glomerulosclerosis and progressive renal impairment (1).
Recently, increasing attention has been paid to the
role of podocytes in the pathogenesis of proteinuric
conditions (2,3). The slit diaphragm, a junction connect-
ing foot processes of neighboring podocytes, represents
the major restriction site to protein ﬁltration (4), and a
causal link between loss of slit diaphragm molecules, such
as nephrin and podocin, and the onset of proteinuria has
been established (5–7). In both human and experimental
diabetic nephropathy, there is a reduction in nephrin
expression, and studies in patients with microalbuminuria
have demonstrated that nephrin downregulation occurs in
an early stage of the disease, supporting the hypothesis of
a role of nephrin loss in glomerular albumin leakage
(8–10). A number of factors, including advanced glycation
end products (10), glomerular hypertension (10,11), angio-
tensin II (10), and inﬂammatory cytokines (12) have been
implicated in the downregulation of slit diaphragm pro-
teins in diabetes, but the precise mechanism is still largely
unknown.
The cannabinoid receptor of type 1 (CB1), a G-protein–
coupled receptor, is expressed predominantly in the cen-
tral nervous system (13), but it has been also found in
peripheral tissues, such as the liver (14), adipose tissue
(15), pancreas (16), and skeletal muscle (17), where it
plays a key role in the control of peripheral energy
metabolism. A recent study has shown that the CB1
receptor is expressed at a low level within the glomeruli
and that CB1 receptor blockade ameliorates proteinuria in
an animal model of obesity-induced nephropathy (18).
Although in obese animals the antiproteinuric effect of
CB1 antagonism is likely related to amelioration of the
metabolic proﬁle, the observation that the CB1 receptor is
present within the glomeruli raises the hypothesis of a
direct effect of signaling through the CB1 receptor on
podocytes and possibly on glomerular permeability to
proteins.
To assess the role of the CB1 receptor in the pathogen-
esis of proteinuria in diabetes, we studied glomerular CB1
receptor expression in streptozotocin (STZ)–induced dia-
betic mice. Furthermore, we tested whether CB1 receptor
blockade affects proteinuria and/or expression of slit
diaphragm and slit diaphragm–associated proteins in this
model.
RESEARCH DESIGN AND METHODS
Materials. All materials were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise stated.
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pyrazole-3-carboxamide (AM251), a CB1 receptor antagonist, was purchased
from Cayman Chemical (Ann Arbor, MI), dissolved in ethanol to a stock
concentration of 3 mg/ml, and stored at 80°C. Stock solutions were diluted
in 18:1:1 ratio of saline/emulphor-620/absolute ethanol immediately prior to
use. AM251 conjugated with 5-carboxytetramethylrhodamine was purchased
from Tocris (Bristol, U.K.).
Animals and induction of diabetes. Both housing and care of laboratory
animals were in accordance with Italian law (D.L.116/1992). Male C57BL6/J
mice from The Jackson Laboratory (Bar Harbor, ME) were maintained on a
normal diet under standard animal house conditions. Diabetes was induced in
mice, aged 8 weeks and weighing 22 g, by intraperitoneal injection of
STZ-citrate buffer (55 mg  kg body wt
1  day
1) delivered in ﬁve consecutive
daily doses. Mice sham-injected with sodium citrate buffer were used as
controls. Diabetes onset was conﬁrmed by blood glucose levels 250 mg/dl 4
weeks after the ﬁrst dose of STZ; only animals with glucose levels 250 mg/dl
(95%) were included in the study.
Experimental protocol. Animals were divided into the following groups:
nondiabetic mice given vehicle (n  7), nondiabetic mice given AM251 (n 
8), diabetic mice given vehicle (n  11), and diabetic mice given AM251 (n 
10). AM251 was administered daily at the dosage of 1 mg/kg i.p. Mice
sham-injected with a mixture 18:1:1 of saline/emulphor-620/absolute ethanol
were used as controls. After 14 weeks of experimental diabetes, mice were
killed by decapitation. The kidneys were rapidly dissected and weighed. The
right kidney was frozen in N2 and stored at 80°C for mRNA and protein
analysis. Half left kidney was ﬁxed in 10% PBS-formalin, then parafﬁn-
embedded for light microscopy; the remaining tissue was embedded in
optimal cutting temperature compound and snap-frozen in N2. For electron
microscopy, 1-mm
3 pieces of renal cortex were ﬁxed in 2% glutaraldehyde, 4%
paraformaldehyde in phosphate buffer 0.12 mol/l for4ha troom temperature,
postﬁxed in 1% osmium tetroxide for 2 h, dehydrated in graded ethanol, and
embedded in Epon 812.
Metabolic and physiological parameters. Before killing, blood samples
were taken via saphenous vein puncture on alert, 4 h–fasted animals, and
glucose levels measured using a glucometer (Accuchek; Roche, Milan, Italy).
Systolic blood pressure was assessed by tail-cuff plethysmography in pre-
warmed unanesthetized animals. Urine was collected over 18 h, with each
mouse individually housed in a metabolic cage and provided with food and
water ad libitum. Urinary albumin concentration was measured by a mouse
albumin ELISA kit (Bethyl Laboratories). Creatinine clearance was estimated
from serum and urine creatinine concentrations, as determined by high-
performance liquid chromatography (19). Glycated hemoglobin was measured
in whole blood samples obtained at the time of killing by quantitative
immunoturbidimetric latex determination (Sentinel Diagnostic, Milan, Italy).
Urinary N-acetylglucosamine (NAG) activity was assessed by colorimetric
assay (Roche), and results were expressed as urinary NAG activity–to–
creatinine ratio.
Immunohistochemistry. After antigen retrieval and blocking, 4-m kidney
parafﬁn sections were incubated overnight at 4°C with either anti-CB1
(Cayman Chemical) or WT-1 (Santa Cruz Biotechnology, Glostrup, Denmark)
primary antibodies; then the speciﬁc staining was detected using the labeled
streptavidin biotin  system horseradish peroxidase (Dako, Glostrup, Den-
mark). Sections were examined using an Olympus microscope (Olympus
Bx4I), digitized with a high-resolution camera (Carl Zeiss, Oberkochen,
Germany). A negative control was included in which the primary antibody was
preincubated with a control peptide. Hippocampus sections were used as
positive control for CB1. The percentage area of staining and the podocyte
number/glomerular area were quantiﬁed by a computer-aided image analysis
system (Axiovision 4.7; Carl Zeiss), where 20 glomeruli and 11 renal tubulo-
interstitial ﬁelds for each section were analyzed. Evaluations were performed
by two independent investigators in a blinded fashion.
Immunoﬂuorescence. Snap-frozen sections (3 m), ﬁxed in cold acetone
and blocked in 3% BSA, were incubated with guinea pig anti-nephrin (Progen
Biotechnik, Maaßstraße, Germany), rabbit anti-podocin, anti-synaptopodin
(Synaptic System, Gottingen, Germany), or anti–zonula occludens-1 (ZO-1;
Zymed Laboratories, San Francisco, CA) primary antibodies. After washing,
ﬂuorescein isothiocyanate–conjugated anti–guinea pig (Santa Cruz Biotech-
nology) and anti-rabbit (Dako) secondary antibodies were added. Sections
were examined using an Olympus epiﬂuorescence microscope (Olympus
Bx4I), digitized with a high-resolution camera (Carl Zeiss). Results were
calculated as percentage positively stained tissue within the glomerular tuft.
On average, 20 randomly selected hilar glomerular tuft cross-sections were
assessed per mouse.
Double immunoﬂuorescence. Double immunoﬂuorescent staining was per-
formed for CB1 and the speciﬁc podocyte marker nephrin. After blocking,
sections were incubated with an anti-nephrin antibody and washed; then a
ﬂuorescein isothiocyanate–conjugated donkey anti–guinea pig antibody was
added. After washing, sections were incubated with a rabbit anti-CB1 antibody
for 18 h at 4°C, washed, and overlaid with a biotinylated swine anti-rabbit IgG
(Dako) and then with Alexa-555–conjugated streptavidin (Invitrogen, Milan,
Italy).
Binding of AM251 to the CB1 receptor was assessed by double ﬂuores-
cence. After immunostaining for the CB1 receptor, as described above,
sections were incubated with the AM251 ﬂuorescent analog at 1 mol/l
concentration for 30 min, then washed, mounted, and visualized by epiﬂuo-
rescence microscopy.
Western blotting. Total kidney was homogenized in radioimmunoprecipita-
tion assay buffer containing 0.5% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 10 mmol/l EDTA, and protease inhibitors. Proteins were separated
by SDS-PAGE and electrotransferred to nitrocellulose membrane. After
blocking in 5% nonfat milk, membranes were incubated with a rabbit anti-CB1
antibody (Calbiochem, Darstadt, Germany) overnight at 4°C. After washing,
secondary anti-rabbit horseradish peroxidase–linked (Amersham) antibody
was added. Detection was performed using SuperSignal West Femto chemi-
luminescence substrate (Pierce, Rockford, IL) and visualized on a Gel-Doc
system (Bio-Rad). Band intensities were quantiﬁed by densitometry. Tubulin
was used as internal control.
Quantitative real-time RT-PCR. Total RNA was extracted from the renal
cortex using TRIZOL reagent (Invitrogen). Total RNA (1 g) was reverse
transcribed into cDNA using the high-capacity reverse transcription kit
(Applied Biosystems, Monza, Italy). CB1, nephrin, podocin, ZO-1, transform-
ing growth factor-1( TGF-1), connective tissue growth factor (CTGF), and
ﬁbronectin mRNA expression was analyzed by TaqMan real-time PCR using
predeveloped TaqMan reagents (Applied Biosystems; CB1: Mm00432621;
nephrin: Mm00497828; podocin: Mm00499929; ZO-1: Mm01320537; TGF-1:
Mm00441724; CTGF: Mm00515790; ﬁbronectin: Mm01256744). Fluorescence
for each cycle was analyzed quantitatively and gene expression normalized
relative to the expression of HPRT. Because housekeeping genes ubiquitously
expressed in the renal cortex do not control for variations in the glomerular
number per specimen or changes in podocyte number (20), WT-1, a podocyte-
speciﬁc gene, was used as endogenous reference for the evaluation of nephrin,
podocin, and ZO-1 mRNA expression.
Podocyte apoptosis. Apoptosis was assessed by the transferase-mediated
dUTP nick-end labeling (TUNEL) method using the ApopTag In Situ Apoptosis
Detection Kit (Millipore, Billerica, MA). Results were expressed as the number
of positive cells per glomerulus in at least 20 random glomeruli. Slides
pretreated with 20,000 units/ml DNase were used as positive control.
Glomerular volume. Glomerular cross-sectional area (AG) was measured in
20 glomerular proﬁles per mouse using a computerized image analysis system
(Axiovision 4.7; Carl Zeiss). The glomerular volume (VG) was then calculated
as VG  /K[AG I
3/2, where 1.38 is the size distributor coefﬁcient and K 
1.01 is the shape coefﬁcient for glomeruli idealized as a sphere (21).
Electron microscopy. Ultrathin sections for ultrastructural examination
were cut with the Ultracut E Reichert-Jung ultramicrotome, stained with
uranylacetate and lead citrate, and examined with the transmission electron
microscope Philips CM 10. Microphotographs were taken using a SIS Mega-
view II digital camera. Mean foot process width (FPW) was assessed as
previously described (22,23) (supplementary Materials, available in an on-
line appendix at http://diabetes.diabetesjournals.org/cgi/content/full/dc09-1336/
DC1).
Data presentation and statistical analysis. Data, presented as means 
SEM, geometric mean (25th–75th percentile), or fold change over control,
were analyzed by Student t test or ANOVA, as appropriate. Least signiﬁcant
difference test was used for post hoc comparisons. Values for P 	 0.05 were
considered signiﬁcant.
RESULTS
Metabolic and physiological parameters in control
and diabetic mice. As shown in Table 1, after 14 weeks of
diabetes both blood glucose and glycated hemoglobin
levels were signiﬁcantly higher in diabetic than in nondi-
abetic mice. Furthermore, compared with sham-injected
control animals, diabetic mice showed a signiﬁcant de-
crease in body weight. Systolic blood pressure was slightly
higher in diabetic than in control mice, but this did not
reach statistical signiﬁcance.
Expression of the CB1 receptor in experimental
diabetes. To establish whether the CB1 receptor is ex-
pressed within the glomeruli and its expression is modu-
lated by diabetes, we studied CB1 expression in kidney
sections from both diabetic and control mice by immuno-
F. BARUTTA AND ASSOCIATES
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cells stained positively for CB1 (Fig. 1A). CB1 protein
expression was enhanced in diabetic mice (Fig. 1B) and
semiquantitative analysis showed that the percentage pos-
itive area was 1.5-fold greater than in the controls (Fig.
1E). Speciﬁcity of the antibody binding was conﬁrmed by
disappearance of the signal when the antibody was preab-
sorbed with a 10-fold excess of control peptide. In the
tubuli, staining for the CB1 receptor was faint and no
differences were observed between control and diabetic
mice (nondiabetic: 2.07  0.73; diabetic: 2.54  0.32; P 
not signiﬁcant) (Fig. 1C and D).
To clarify which glomerular cell type overexpressed the
CB1 receptor, double-labeling immunoﬂuorescence was
performed in diabetic mice for the detection of both CB1
and nephrin. The CB1 receptor was expressed primarily by
glomerular podocytes as the positive staining for nephrin
(Fig. 1L) colocalized with CB1 staining (Fig. 1I), resulting
in a partial yellow overlap (Fig. 1M and N).
To conﬁrm immunohistochemistry ﬁndings with more
quantitative techniques, we measured CB1 mRNA and
protein expression in total renal cortex by real-time PCR
and immunoblotting. There was a signiﬁcant two-fold
increase in CB1 mRNA levels in diabetic mice (Fig. 1F)
compared with nondiabetic control animals. Immunoblot-
ting showed a band migrating at 60 kDa, corresponding
to the reported molecular weight of CB1 (Fig. 1G), and
densitometric analysis demonstrated that CB1 protein
expression was signiﬁcantly increased in the diabetic mice
(Fig. 1G and H).
AM251 binding to the CB1 receptor. As shown in Fig.
1O–Q, glomerular staining using a ﬂuorescent AM251
analog overlapped with the immunoﬂuorescent staining
for the CB1 receptor, conﬁrming that AM251 binds to the
CB1 receptor.
Effect of treatment with AM251 on metabolic and
physiological parameters. As shown in Table 1, treat-
ment with AM251 did not affect the degree of glycemic
control because both blood glucose and glycated hemo-
globin levels were similar in treated and untreated diabetic
animals. In addition, in both diabetic and control animals
administration of AM251 did not alter body weight. Finally,
no differences were observed in systolic blood pressure.
Effect of CB1 receptor blockade on albuminuria,
NAG activity, and renal function. After 14 weeks of
diabetes, there was a more than 10-fold increase in urinary
albumin excretion rate in diabetic compared with nondia-
betic animals. Treatment with AM251 did not alter albu-
minuria in the controls, but induced a signiﬁcant 50%
reduction in albumin excretion rate levels in the diabetic
mice (Table 1). Results were similar when they were
expressed as urinary albumin/creatinine ratio (nondia-
betic: 146  6.88; nondiabetic  AM251: 147.9  33.87;
diabetic: 2447.5  607.7; diabetic  AM251: 806.3  190.5;
P 	 0.001 diabetic vs. others). Urinary NAG activity/
creatinine ratio, a marker of tubular damage, was slightly
increased in diabetic mice compared with controls, al-
though not signiﬁcantly. In addition, no differences were
observed between treated and untreated diabetic mice
(nondiabetic: 88.11  8.37; nondiabetic  AM251: 93.16 
16.52; diabetic: 178.13  21.43; diabetic  AM251: 180.64 
40.86 units/g; P  not signiﬁcant). Renal function was
similar among groups as assessed by measurement of
creatinine clearance (nondiabetic: 0.38  0.07; diabetic:
0.41  0.1; diabetic  AM251: 0.5  0.1 ml/min; P  not
signiﬁcant).
Effect of AM251 on nephrin, podocin, ZO-1, and
synaptopodin expression. To clarify the underlying
mechanism of the beneﬁcial effect of CB1 blockade on
albuminuria, we assessed the effect of treatment with
AM251 on the expression of nephrin, podocin, ZO-1, and
synaptopodin by immunoﬂuorescence. After 14 weeks of
diabetes, there was a signiﬁcant reduction in nephrin,
podocin, and ZO-1 protein expression, and this effect was
completely prevented in diabetic mice treated with AM251
(Fig. 2A–F). No signiﬁcant changes in synaptopodin pro-
tein levels were observed among groups (Fig. 2G and H).
We also assessed nephrin, podocin, and ZO-1 mRNA in
total renal cortex from all groups by real-time PCR and
found a signiﬁcant reduction in nephrin, podocin, and
ZO-1 mRNA levels in diabetic compared with control
mice. Treatment with AM251 prevented diabetes-induced
nephrin and podocin mRNA downregulation (Fig. 3A and
B). A similar trend was also observed for ZO-1, although it
did not reach statistical signiﬁcance (Fig. 3C).
Effect of CB1 receptor blockade on podocyte injury.
To establish whether in diabetic mice treated with AM251,
podocyte protein expression was preserved because CB1
blockade prevented podocyte damage, podocyte number,
apoptosis, and ultrastructure were assessed by WT-1 stain-
ing, TUNEL assay, and electron microscopy, respectively.
The number of both WT-1– and TUNEL-positive cells per
glomerular cross-sectional area displayed in a podocyte
distribution did not differ among groups (Fig. 4) (nondia-
betic: 2.0  0.5; diabetic: 2.2  0.4; nondiabetic  AM251:
2.5  0.3; diabetic  AM251: 2.1  0.5, TUNEL-positive
cells per 100 glomeruli; P  not signiﬁcant). Electron
microscopy analysis did not show any evidence of ultra-
structural glomerular (Fig. 4A–F) and tubular (Fig. 5G–L)
damage in the studied animals. In particular, the normal
arrangement of interdigitating foot processes was main-
tained in all groups, and podocyte foot processes appeared
tall and narrow in both treated and untreated diabetic
mice (Fig. 5A–F). Furthermore, mean FPW was compara-
TABLE 1
General assessment parameters in each of the study groups
Nondiabetic Nondiabetic  AM251 Diabetic Diabetic  AM251
Body wt (g) 28.71  1.13 29.41  0.56 25.23  0.84* 25.86  0.69*
Blood glucose (mg/dl) 120  5.81 104  12.07 411  36.07† 386  36.64†
Glycated Hb (%) 4.23  0.05 4.40  0.16 12.93  0.32† 12.49  0.24†
sBP (mmHg) 101  3.30 98  3.30 119  10.50 118  3.79
Kidney/body wt 6.62  0.03 6.46  0.19 8.42  0.99 7.34  0.29
AER (g/18 h) 33.4 (25.1–40.2) 37.5 (12.6–126.4) 336.6 (164.9–778.5)† 153.1 (70.7–298.1)†‡
Data are shown as means  SE orgeometric mean (25th–75th percentile). sBP, systolic blood pressure; AER, albumin excretion rate. *P 	
0.05 diabetic and diabetic  AM251 vs. nondiabetic and nondiabetic  AM251; †P 	 0.001 diabetic and diabetic  AM251 vs. nondiabetic
and nondiabetic  AM251; ‡P 	 0.01 diabetic  AM251 vs. diabetic.
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AM251: 352  1.27; diabetic: 375  1.11; diabetic  AM251:
364  0.99 nm; P  not signiﬁcant).
Effect of CB1 blockade on glomerular hypertrophy
and early markers of ﬁbrosis. Glomerular volume was
signiﬁcantly increased in diabetic mice compared with
control animals and this effect was not altered by treat-
ment with AM251 (nondiabetic: 136  10.33; diabetic:
358  19.06; nondiabetic  AM251: 127  4.98; diabetic 
AM251: 369  5.72 m
3; P 	 0.05 diabetic and diabetic 
AM251 vs. nondiabetic).
At electron microscopy, the degree of mesangial expan-
sion and glomerular basement membrane thickening was
very mild in diabetic mice, and no major differences were
observed among groups (Fig. 4A–D). However, in the renal
cortex levels of mRNA encoding for ﬁbronectin, TGF-1,
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control animals. Treatment of diabetic mice with AM251
did not affect the overexpression of these markers of
ﬁbrosis, suggesting that CB1 blockade does not have
antiﬁbrotic properties in this model (Figure 6A–C).
DISCUSSION
In this study, we have provided evidence that in experi-
mental diabetes the CB1 receptor is overexpressed within
the glomeruli, predominantly by glomerular podocytes.
Second, we have shown that blockade of the CB1 receptor
with AM251 ameliorates albuminuria and prevents down-
regulation of nephrin, podocin, and ZO-1. Taken together,
these data suggest a role of the CB1 receptor in the
pathogenesis of proteinuria in diabetes.
In nondiabetic mice, only a few glomerular cells stained
positively for the CB1 receptor, but after 14 weeks of
experimental diabetes there was a signiﬁcant 1.5-fold
increase in glomerular CB1 expression. A previous study
has shown that the CB1 receptor is expressed at low level
in rat kidneys, but no differences in renal CB1 expression
were observed between Zucker fatty rats and lean animals
(18). Therefore, this is the ﬁrst evidence of glomerular CB1
overexpression in experimental diabetes and, to our
knowledge, in any renal disease.
In agreement with previous data in rat kidneys (18),
immunoreactivity for CB1 was predominantly localized to
the glomeruli. A faint signal was also detectable in the
tubuli, but it was not enhanced in the diabetic mice. Both
pattern of staining and colocalization with the podocyte
marker nephrin strongly indicate that in diabetic mice the
CB1 receptor was primarily overexpressed by glomerular
podocytes. This is not surprising because similarities have
been reported between podocytes and neurons (24,25), the
predominant CB1 receptor–expressing cell type in physi-
ological conditions (13). The underlying mechanism/s of
CB1 receptor induction in diabetic podocytes is entirely
unknown. However, oxidative stress, which is enhanced in
the diabetic glomeruli, is known to induce CB1 receptor
expression in other cell types (26).
Consistent with our immunohistochemical data, we
found a signiﬁcant 1.8- to 2-fold increase in CB1 both
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FIG. 3. CB1 blockade prevented diabetes-induced reduction of both
nephrin and podocin gene expression. Total RNA was extracted from
the renal cortex of nondiabetic and diabetic mice treated with either
vehicle (diabetic mice) or the CB1 antagonist AM251 (diabetic 
AM251) for 14 weeks. Nephrin (A), podocin (B), and ZO-1 (C) mRNA
levels were measured by real-time PCR and corrected for the expres-
sion of WT-1 as described in the “Research Design and Methods”
section (*P < 0.05 diabetic vs. nondiabetic and diabetic  AM251; #P <
0.05 diabetic vs. nondiabetic).
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FIG. 4. Podocytes number in diabetic and nondiabetic mice treated
with either vehicle or AM251. WT-1 protein expression was assessed by
immunohistochemistry in the glomeruli from nondiabetic and diabetic
mice treated for 14 weeks with either vehicle or the CB1 receptor
antagonist AM251. Quantiﬁcation of WT-1–positive cells per glomeru-
lar area is shown in the graph.
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betic mice as assessed by immunoblotting and real-time
PCR. Diabetes-induced enhanced transcription of the CB1
receptor is a potential underlying mechanism as both
activator protein 1 (AP-1) and nuclear factor-
B (27,28),
the transcription factors predominantly implicated in the
pathogenesis of diabetic nephropathy, have binding sites
on the promoter region of the CB1 receptor gene (29).
To establish whether upregulation of the CB1 receptor
in podocytes plays a role in the pathogenesis of protein-
uria in diabetes, we studied the effect of treatment with
AM251. AM251, a potent and speciﬁc CB1 receptor inverse
agonist (30–33), is structurally very close to rimonabant,
but exhibits better binding afﬁnity and selectivity for the
CB1 receptor (33). In our model, selectivity of AM251
binding to the CB1 receptor was indirectly conﬁrmed by
colocalization of AM251 and CB1 within the diabetic
glomeruli. AM251 was administered daily at the dosage of
1 mg/kg on the basis of previous studies that have proven
both efﬁcacy and safety of this dose in mice (34,35).
Delivery was via intraperitoneal injection to ensure that all
animals were given an equal amount of drug. After 14
weeks of diabetes, there was a 10-fold increase in albu-
minuria in diabetic mice compared with controls. Treat-
ment with AM251 induced a signiﬁcant 50% reduction in
albuminuria in diabetic mice, supporting the hypothesis
that signaling through the CB1 receptor contributes to
enhanced glomerular permeability to albumin.
Administration of AM251 did not affect body weight in
either diabetic or control mice. This is in agreement with
previous reports showing that CB1 blockade prevents
weight gain in animals with diet-induced obesity, but is
much less efﬁcacious at exerting this effect in lean animals
fed a standard diet (36–38). Furthermore, blood glucose
levels, glycated hemoglobin, and systolic blood pressure
were similar in treated and untreated diabetic mice, con-
sistent with the antiproteinuric effect of CB1 blockade
observed in these mice being independent of both meta-
bolic and hemodynamic factors. A signiﬁcant reduction in
proteinuria has been recently reported in obese Zucker
fatty rats treated with rimonabant (18); however, in this
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FIG. 5. Transmission electron microscopy analysis. Representative
electron microscopy images of glomeruli (upper panels) and tubuli
(lower panels) from nondiabetic (A, B, G, and H: magniﬁcation 2600)
and diabetic mice (C, D, I, and L: magniﬁcation 2600; E and F:
magniﬁcation 6000) treated for 14 weeks with either vehicle (A, C, E,
G, and I) or the CB1 receptor antagonist AM251 (B, D, F, H, and L). In
A and B the glomerular structure is normal. Glomeruli from diabetic
mice (C and D) display some degree of mesangial expansion, indepen-
dent of treatment. At higher magniﬁcation (E and F) the podocyte foot
processes are regularly shaped and only a minimal irregularity in the
thickness of the GBM can be observed in E. Tubular structure appears
normal in both control and diabetic mice (G and I) and unaffected by
treatment with AM251 (H and L).
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FIG. 6. CB1 blockade did not affect overexpression of ﬁbronectin,
TGF-1, and CTGF in diabetic mice. Total RNA was extracted from the
renal cortex of nondiabetic and diabetic mice treated with either
vehicle (diabetic mice) or the CB1 antagonist AM251 (diabetic 
AM251) for 14 weeks. TGF-1 (A), CTGF (B), and ﬁbronectin (C)
mRNA levels were measured by real-time PCR and corrected for the
expression of the gene housekeeping HPRT as described in the “Re-
search Design and Methods” section (*P < 0.05 diabetic and diabetic 
AM251 vs. nondiabetic).
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uli, and the antiproteinuric effect was most likely due to
amelioration of the metabolic proﬁle because it was
associated with body weight loss and diminution of both
blood glucose and lipid levels. In our study, we have
purposely chosen an animal model of type 1 diabetes
without obesity, insulin resistance, and lipid abnormalities
to ensure that the beneﬁcial effects of CB1 blockade were
independent of changes in metabolism.
To clarify the mechanism/s of the beneﬁcial effect of
AM251, we tested whether CB1 receptor blockade pre-
vents downregulation of podocyte proteins implicated in
the maintenance of glomerular permselectivity to proteins.
After 14 weeks of diabetes, there was a signiﬁcant reduc-
tion in nephrin, podocin, and ZO-1 both mRNA and protein
expression. Treatment with AM251 prevented diabetes-
induced downregulation of nephrin, podocin, and ZO-1
protein expression. Results were conﬁrmed by mRNA
analysis for both nephrin and podocin, and a similar trend
was also observed for ZO-1. Loss of slit diaphragm and slit
diaphragm–associated proteins has been implicated in the
pathogenesis of proteinuria (2); therefore, downregulation
of nephrin, podocin, and ZO-1 is a possible mechanism
whereby CB1 overexpression may lead to increased glo-
merular permeability to albumin.
The number of both total and apoptotic podocytes was
not increased in diabetic mice. Furthermore, there was no
evidence of podocyte foot process effacement at the
ultrastructural level or changes in mean FPW. It is, thus,
unlikely that levels of nephrin, podocin, and ZO-1 were
normal in diabetic mice treated with AM251 because of
prevention of podocyte damage. These data also suggest
that in early experimental diabetes, downregulation of slit
diaphragm proteins precedes the development of podo-
cyte foot process effacement/loss and that podocyte struc-
tural damage is not strictly required for the development
of proteinuria. Consistent with this view, in nephrin
knockout animals proteinuria occurs even in the absence
of any defects in the podocyte foot processes (39). The
degree of nephrin reduction required for the development
of proteinuria is unknown; however, the parallel down-
regulation of other slit diaphragm proteins is likely to
cause a rise in this threshold level (40).
In the diabetic mice, tubular ultrastructure was normal
and urinary activity of NAG, a marker of tubular damage,
was comparable in treated and untreated mice. Therefore,
prevention of tubular injury is not a likely explanation of
AM251 antiproteinuric activity. However, we cannot ex-
clude the possibility that at a later stage of experimental
diabetes, when severe tubular damage occurs, CB1 block-
ade may have further beneﬁcial effects due to prevention
of tubulointerstitial injury, as previously shown in the
Zucker fatty rat model (18).
Glomerular hypertrophy and accumulation of extracel-
lular matrix components, which is mediated predomi-
nantly by the prosclerotic cytokines TGF-1 and CTGF,
are other characteristic features of diabetic nephropathy
(1). In our study, after 14 weeks of mild diabetes, C57BL6/J
mice, which are relatively resistant to the development of
glomerulosclerosis, did not show major ultrastructural
abnormalities in the mesangium and the glomerular base-
ment membrane. However, there was a signiﬁcant in-
crease in both glomerular volume and renal mRNA
expression of ﬁbronectin, TGF-1, and CTGF in diabetic
mice. These diabetes-induced effects were left unchanged
by treatment with AM251, indicating failure of CB1 block-
ade in interfering with glomerular hypertrophy and renal
ﬁbrogenesis. In animal models of chronic liver injury,
blockade of the CB1 receptor decreases ﬁbrosis by lower-
ing hepatic TGF-1 expression and reducing accumulation
of ﬁbrogenic cells (14). The different effect of CB1 block-
ade on renal and liver ﬁbrosis is not entirely surprising
because the cell types overexpressing the CB1 receptor in
liver cirrhosis, namely myoﬁbroblasts and hepatic stellate
cells, have much greater proﬁbrotic potential than podo-
cytes. In addition, a tissue-speciﬁc effect of CB1 receptor
activation cannot be excluded.
In conclusion, our ﬁndings may have important implica-
tions for diabetic nephropathy in humans. Proteinuria is a
characteristic feature of diabetic nephropathy and a key
determinant of progression (1). Nephrin is downregulated
in early diabetic nephropathy, and this has been impli-
cated in the pathogenesis of the diabetic proteinuria (10).
Our data, showing upregulation of CB1 receptors in podo-
cytes and a beneﬁcial effect of AM251 on both albuminuria
and nephrin loss, suggest that an elevated CB1 receptor
tone (41) is also involved in the pathogenesis of the
diabetic proteinuria and identify a new target for thera-
peutic intervention.
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